Nipocalimab (Imaavy®) for Generalized Myasthenia Gravis (gMG) in Adult and Adolescent Patients
Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for nipocalimab (Imaavy) for the treatment of generalized myasthenia gravis (gMG) in adults (≥18 years) and adolescent patients (12 to 18 years) who are antibody positive (anti-acetylcholine receptor [AChR], anti-muscle-specific tyrosine kinase [MuSK], or anti-low-density lipoprotein receptor-related protein 4 [LRP4]).